As filed with the Securities and Exchange Commission on February 17, 2026. Registration No. 333-293179 PROFUSA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Name, address, including zip code, and telephone number, including area code, of agent for service) Delaware 3841 86-343 ...

As filed with the Securities and Exchange Commission on February 13, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROFUSA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 86-3437271 (I.R.S. Employer Identification Number) 626 Bancroft Way, Suite A Be ...

As filed with the Securities and Exchange Commission on February 13, 2026 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROFUSA, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Delaware 3841 86-3437271 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (I.R.S. Employer Identification Number) 626 Bancroft Way, Suite A Berkeley, CA 94710 (925) 997-6925 (Address, including zip code, and telephone number, incl ...

As filed with the Securities and Exchange Commission on February 3, 2026. Registration No. 333-________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROFUSA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 86-3437271 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 626 Bancroft Way ...

Financial Performance - For the three months ended September 30, 2025, the company incurred a net loss of $22.2 million, compared to a net loss of $2.5 million for the same period in 2024, representing an increase of 788% [200]. - For the nine months ended September 30, 2025, the company incurred a net loss of $27.3 million, compared to a net loss of $7.0 million for the same period in 2024, indicating a 289% increase [200]. - Net loss increased to $22,192,000 in Q3 2025 from $2,497,000 in Q3 2024, a change of 789% [224]. - The company has incurred recurring annual losses since inception, indicating ongoing financial challenges [200]. - The company’s net loss for the nine months ended September 30, 2025, was $27.3 million, adjusted for non-cash charges of $10.7 million [247]. Cash Flow and Financing - The company reported cash used in operating activities of $11.1 million for the nine months ended September 30, 2025, compared to $1.8 million for the same period in 2024, reflecting a significant increase in cash burn [200]. - The company obtained net cash from financing activities of $14.9 million for the nine months ending September 30, 2025, compared to $1.8 million for the same period in 2024, showing a substantial increase in financing [201]. - Cash provided by financing activities was $14.9 million for the nine months ended September 30, 2025, compared to $1.8 million in the same period of 2024, reflecting a 718% increase [249][250]. - Cash and cash equivalents on hand, along with proceeds from the Business Combination and PIPE Investment, total approximately $14.5 million, which includes $9 million from the first tranche and $2 million from the second tranche of a convertible note [244]. - The company may need to seek additional equity or debt financing after September 30, 2025, depending on future capital requirements and market conditions [245]. Operating Expenses - General and administrative expenses surged by $20,220,000 or 2636% to $20,987,000 in Q3 2025, primarily due to transaction costs related to the Business Combination [226]. - Research and development expenses increased by $311,000 or 76% to $722,000 in Q3 2025, driven by higher personnel and regulatory fees [225]. - Total operating expenses rose to $21,709,000 in Q3 2025 from $1,178,000 in Q3 2024, reflecting a change of 1743% [224]. - General and administrative expenses for the nine months ended September 30, 2025, increased by $20,418,000 or 941% to $22,587,000 compared to the same period in 2024 [231]. Business Development and Strategy - The company launched Lumee Oxygen in Europe in 2023 and plans to launch Lumee Glucose in 2025, pending regulatory approval [196]. - The company is targeting both public and private payors for coverage of Lumee Glucose, which is designed for easy insertion with a hypodermic needle, differentiating it from other continuous glucose monitoring systems [198]. - The company is focused on building its commercial infrastructure in Europe and the United States while exploring partnerships in Asia [203]. - The company is negotiating the formation of the APAC Joint Venture to develop and commercialize products in the Asia Pacific region [238]. Grants and Obligations - Government grant revenue decreased to $0 in Q3 2025 from $75,000 in Q3 2024, a change of -100% [224]. - Total contractual obligations as of September 30, 2025, amount to $21.1 million, with $6.7 million due in 2025 and $14.4 million in 2026 [251]. Other Financial Metrics - Interest expense decreased by $904,000 or 84% to $(169,000) in Q3 2025, attributed to the repayment of convertible notes [228]. - The company raised gross proceeds of $98.0 million from convertible preferred stock and convertible notes from inception through September 30, 2025 [235]. - The fair value of the Ascent PIPE convertible loan is estimated at $14.4 million as of September 30, 2025, classified as a Level 3 financial instrument due to the absence of observable market inputs [256]. - Changes in fair value of the related party convertible loan are recognized in earnings each period, with a 100 basis point change in the discount rate affecting fair value by approximately $17 thousand [260][259]. - Cash used in investing activities for the nine months ended September 30, 2025, was $1 million, compared to no cash used in the same period of 2024 [246][248]. - Estimated near-term capital requirements through September 30, 2025, are approximately $19.4 million, primarily for research and development, manufacturing, and marketing of Lumee Oxygen and Lumee Glucose devices [245].

As filed with the Securities and Exchange Commission on October 9, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROFUSA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 26-4589529 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 626 Bancroft Way Suite A Berkeley, CA 94710 (925 ...

As filed with the Securities and Exchange Commission on September 16, 2025. Registration No. 333-289958 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________________ PROFUSA, INC. (Exact name of registrant as specified in its charter) ___________________________________ | Delaware | 3841 | 26-4589529 | | --- | --- | --- | | (State or other juri ...

As filed with the Securities and Exchange Commission on August 29, 2025. Registration No. 333-________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________________ PROFUSA, INC. (Exact name of registrant as specified in its charter) ___________________________________ | Delaware | 3841 | 26-4589529 | | --- | --- | --- | | | (Primary Standard Industrial | (I.R.S. Employer | | | Classification Code ...

As filed with the Securities and Exchange Commission on August 22, 2025. Registration No. 333-289461 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________________ PROFUSA, INC. (Exact name of registrant as specified in its charter) ___________________________________ | Delaware | 3841 | 26-4589529 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial ...

As filed with the Securities and Exchange Commission on August 21, 2025. Registration No. 333-289461 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________________ PROFUSA, INC. (Exact name of registrant as specified in its charter) ___________________________________ | Delaware | 3841 | 26-4589529 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial ...